| 1. |
|
|
| 2. |
- Woodard, J., et al.
(författare)
-
Zircon and monazite geochronology of deformation in the Pielavesi Shear Zone, Finland: multistage evolution of the Archaean–Proterozoic boundary in the Fenoscandian Shield.
- 2017
-
Ingår i: Journal of the Geological Society. - : Geological Society of London. - 0016-7649 .- 2041-479X. ; 174, s. 255-267
-
Tidskriftsartikel (refereegranskat)abstract
- The Raahe–Ladoga Shear Complex is a major crustal structure representing the Archaean–Palaeoproterozoic boundary in the Fennoscandian Shield. The complex developed during the Svecofennian Orogeny (c. 1.9 – 1.8 Ga) beginning with regional thrust tectonic phases D1 and D2, followed by large-scale shearing events D3 and D4. The Pielavesi Shear Zone is a vertical north–south-trending shear zone within the Raahe–Ladoga Shear Complex formed during regional D3 shearing and later reactivated during the regional D4 phase. Three north–south-trending elongate granitoid intrusions were selected as representative of silicic melts that intruded the transtensional Pielavesi Shear Zone during the regional D3 phase. The oriented magmatic fabric of the granitoids indicates that they intruded coeval to the deformation event. The zircon U–(Th)–Pb secondary ionization mass spectrometry (SIMS) ages of these intrusions (1888 ± 4, 1884 ± 6 and 1883 ± 5 Ma) overlap within error and provide a direct age for the regional D3 deformation. εHf(T)(−1.1 to +3.4) and εNd(T) (−1.2 to +0.4) values from these granitoids are both consistent with a predominantly juvenile source affected by a minor Archaean component. U–(Th)–Pb SIMS analyses of metamorphic monazite formed within a crosscutting blastomylonite provide an age for the regional D4phase and associated fluid activity of 1793 ± 3 Ma.
|
|
| 3. |
- Johansson, Jarkko, et al.
(författare)
-
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
- 2019
-
Ingår i: Neuropsychopharmacology. - : Nature Publishing Group. - 0893-133X .- 1740-634X. ; 44:9, s. 1667-1673
-
Tidskriftsartikel (refereegranskat)abstract
- Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. They may have additional therapeutic utility also in the absence of opioid agonist drugs, but the onset and duration of action at brain MORs have been inadequately characterized to allow such projections. This study provides initial characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone administration to healthy volunteers in the absence of a competing opioid agonist. Fourteen participants were scanned twice using positron emission tomography (PET) and [11C]carfentanil, a selective MOR agonist radioligand. Concentrations of naloxone in plasma and MOR availability (relative to placebo) were monitored from 0 to 60 min and at 300–360 min post naloxone. Naloxone plasma concentrations peaked at ~20 min post naloxone, associated with slightly delayed development of brain MOR occupancy (half of peak occupancy reached at ~10 min). Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively. The estimated half-life of occupancy disappearance was ~100 min. The rapid onset of brain MOR occupancy by IN naloxone, evidenced by the rapid onset of its action in opioid overdose victims, was directly documented in humans for the first time. The employed high temporal-resolution PET method establishes a model that can be used to predict brain MOR occupancy from plasma naloxone concentrations. IN naloxone may have therapeutic utility in various addictions where brain opioid receptors are implicated, such as gambling disorder and alcohol use disorder.
|
|
| 4. |
|
|
